Clinical Trials Logo

Recurrent Clostridium Difficile Infection clinical trials

View clinical trials related to Recurrent Clostridium Difficile Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT03353506 Not yet recruiting - Enterocolitis Clinical Trials

Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection

Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

Fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile infection (RCDI) has traditionally been offered as fecal slurry administered by enema, nasogastric tube or endoscopy. Frozen oral capsules have also shown efficacy. The potential advantage of lyophilized FMT is the relative ease of manufacturing and storage compared with fecal slurry. Sterile fecal filtrate has previously been shown to prevent Clostridium difficile infection (CDI) recurrence, suggesting that live bacteria may not be needed. This study will compare lyophilized sterile fecal filtrate (LSFF) with lyophilized FMT (LFMT) in the treatment of recurrent Clostridium difficile infection (RCDI).

NCT ID: NCT01925417 Completed - Clinical trials for Recurrent Clostridium Difficile Infection

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

PUNCH CD
Start date: August 2013
Phase: Phase 2
Study type: Interventional

This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.

NCT ID: NCT01226992 Terminated - Clinical trials for Recurrent Clostridium Difficile Infection

Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin

Start date: October 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Recurrent CDI is a growing problem with few treatment options that provide lasting effect. Fecal transplantation has been shown in several case series to be successful in controlling recurrent CDI. The current study is a non-blinded, randomized controlled trial comparing fecal transplantation with a 6 week taper of oral vancomycin for the treatment of refractory CDI. Approximately 146 patients will be enrolled over one year. Participants in the study will be followed for 120 days, and will be given the opportunity to cross over to the alternative intervention arm if a relapse in symptoms occurs. The primary outcome measure will be recurrence of toxin-confirmed CDI within 120 days of starting the intervention. Secondary outcomes include: early recurrence of symptoms within 14 days, relapse within 120 days (same strain of C. difficile), attributable mortality, hospitalization and serious adverse events.

NCT ID: NCT01202630 Suspended - Clinical trials for Recurrent Clostridium Difficile Infection

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of BIO-K+ CL1285 for prevention of recurrent Clostridium difficile infection.